Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

ClinicalTrials.gov ID: NCT06921785

Public ClinicalTrials.gov record NCT06921785. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 21, 2026, 12:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Randomised, Open-label, Sponsor-blinded, Multicentre Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Study identification

NCT ID: NCT06921785
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: AstraZeneca; Industry
Enrollment: 1,220 participants

Conditions and interventions

Conditions

Hepatocellular Carcinoma

Interventions

Atezolizumab Drug
Bevacizumab Drug
Rilvegostomig Drug
Tremelimumab Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 5, 2025
Primary completion: Mar 15, 2029
Completion: Mar 14, 2030
Last update posted: May 10, 2026

2025 – 2030

United States locations

U.S. sites: 32
U.S. states: 19
U.S. cities: 29

Facility	City	State	ZIP	Site status
Research Site	Phoenix	Arizona	85054	Recruiting
Research Site	Tucson	Arizona	85719	Not yet recruiting
Research Site	Palo Alto	California	94304	Recruiting
Research Site	Santa Monica	California	90404	Not yet recruiting
Research Site	New Haven	Connecticut	06511	Recruiting
Research Site	Newark	Delaware	19713	Not yet recruiting
Research Site	Jacksonville	Florida	32224	Recruiting
Research Site	Atlanta	Georgia	30318	Not yet recruiting
Research Site	Atlanta	Georgia	30322	Withdrawn
Research Site	Chicago	Illinois	60637	Not yet recruiting
Research Site	Indianapolis	Indiana	46202	Not yet recruiting
Research Site	Shreveport	Louisiana	71103	Not yet recruiting
Research Site	Detroit	Michigan	48202	Not yet recruiting
Research Site	Grand Rapids	Michigan	49503	Recruiting
Research Site	Rochester	Minnesota	55905	Recruiting
Research Site	New Brunswick	New Jersey	08901	Recruiting
Research Site	New York	New York	10029	Recruiting
Research Site	New York	New York	10032	Not yet recruiting
Research Site	New York	New York	10065	Not yet recruiting
Research Site	Cleveland	Ohio	44195	Withdrawn
Research Site	Philadelphia	Pennsylvania	19107	Not yet recruiting
Research Site	Pittsburgh	Pennsylvania	15232	Not yet recruiting
Research Site	Austin	Texas	78705	Recruiting
Research Site	Dallas	Texas	75390	Withdrawn
Research Site	El Paso	Texas	79902	Not yet recruiting
Research Site	Houston	Texas	77030	Not yet recruiting
Research Site	San Antonio	Texas	78240	Recruiting
Research Site	Tyler	Texas	75702	Not yet recruiting
Research Site	Arlington	Virginia	22201	Not yet recruiting
Research Site	Salem	Virginia	24153	Recruiting
Research Site	Seattle	Washington	98109	Not yet recruiting
Research Site	Milwaukee	Wisconsin	53226	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 181 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06921785, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 10, 2026 · Synced May 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06921785 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →